EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Reversal of Premature Hair Graying Treated with a Topical Formulation Containing α-Melanocyte-Stimulating Hormone Agonist (Greyverse Solution 2%)

Dipali Chavan

International Journal of Trichology · 2022-11 · 14 (6) · 207-209

DOI: 10.4103/ijt.ijt_85_22 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT With aging, hair graying is a common sign resulting from complex regulation of melanogenesis. Multiple factors control the stimulation of melanogenesis at the level of the hair follicle, including melanin-stimulating hormone (MSH), adrenocorticotropic hormone, endothelin-1, prostaglandins, leukotrienes, neutrophils, fibroblast growth factor, nitric oxide, catecholamines, Vitamins, and minerals. Premature hair graying (PHG) has a major impact on the cosmesis, self-credibility, and social life of the affected individual. Currently, there is no medical treatment available for PHG. We present a case of a 25-year-old female with a history of graying of hair on the scalp. Clinical diagnosis revealed it as a case of premature graying/canities. She was prescribed a topical formulation (Greyverse solution) containing palmitoyl tetrapeptide 20, a biomimetic biopeptide of α -MSH for treating her PHG. The formulation was applied 1 mL twice daily directly on the affected part of the scalp. Hair supplements containing a combination of biotin and calcium pantothenate once daily orally were also prescribed. After 3 months, the patient showed some improvement, and the dose of the topical solution was reduced to 1 mL once daily. After 5 months, the patient achieved >90% conversion of gray hair to black hair.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →